Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
17-beta estradiol · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Individual dose | EXPERIMENTAL | - |
| Fixed dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 17-beta estradiol | DRUG | 5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally |
Inclusion Criteria: * Turner Syndrome * Treatment with growth hormone * Bone age minimum 12 years and maximum 14 years * Clear signs of ovarian insufficiency * Well documented growth rate during the last 12 months Exclusion Criteria: * Signs of spontaneous puberty * Known or suspected hypersensit...
17-beta estradiol is being studied for use in girls with Turner syndrome, a genetic disorder. It is intended to induce puberty in this patient population. The drug is currently in Phase 3 clinical development and is being developed by Novo Nordisk A/S.
17-beta estradiol is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the stock exchange under the ticker NVO. The drug is currently in Phase 3 clinical trials for the treatment of Turner syndrome, a genetic disorder.
17-beta estradiol is in Phase 3 clinical development. It is an investigational drug being studied for the induction of puberty in girls with Turner syndrome. The Phase 3 trial has been completed, and the drug is not yet approved for this use.
17-beta estradiol has one completed Phase 3 clinical trial, identified as NCT01710696. This trial, titled 'Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome,' enrolled 50 female participants in Spain. The study was randomized, double-blind, and controlled.
17-beta estradiol is a form of estradiol, a naturally occurring estrogen hormone. In the context of this clinical development program, it is being studied specifically for its ability to induce puberty in girls with Turner syndrome. The drug is being developed by Novo Nordisk A/S.